This Biotech Fund Sold $8 Million, Yet Remains Bullish on Terns
A biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
Find the best retirement strategies tailored for your 60s. Make the most of your savings and prepare for a rewarding retirement.
6,694 articlesA biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
A multibillion-dollar air defense push in Greece is drawing investor attention to Lockheed Martin and other defense c...
Rising housing costs strain households and the broader economy. Smart tax policy can lower those costs by acceleratin...
Two early leaders in the electric air taxi race collide with a policy signal that could tilt the field. This analysis...
A fresh take on spotting a possible dark-horse in the driverless vehicle arena. Learn the signals, risks, and how to ...
Qualcomm is navigating a tough start to 2026. A memory crunch, potential shifts with Apple, and a large buyback are m...
This week brought a sharp decline in lenz therapeutics stock plummeted as concerns about revenue growth and financing...
BlackRock's Larry Fink presents two stark paths for oil and markets tied to the Iran conflict, challenging households...
Geopolitics can shake travel stocks fast. This article breaks down how Carnival, the world’s largest cruise operator,...
A trio of durable cash-flow stocks offer steady dividends and room to grow, giving investors a balanced path through ...
Shares FISERV rising today can reflect more than a quick swing. This article breaks down the catalysts, the business ...
Investors often ask where will stock years? BYD’s five-year path holds both promise and risk. This guide breaks down ...